Enhanced blood product antiviral process and product produced

Details Enhanced blood product antiviral process and product produced Enhanced blood product antiviral process and product produced

1989-10-20

1992-07-07

Rosen, Sam

Drug, bio-affecting and body treating compositions

Extract, body fluid, or cellular material of undetermined...

Blood

424530, 424533, 435 2, A61K 3514

Patent

active

051281490

ABSTRACT:
A transfusion blood product container for the introduction of one or more blood products, such as whole blood, platelet concentrations, leukocyte concentrations, plasma, phasma derivatives, whole blood fractions, and combinations thereof, for transfusing the patient and an amount of one or more glycyrrhizic triterpenoid compounds sufficient to comprise from 0.05 to 10.0 wt/%, preferably from about 0.5 to about 3 wt/%, of the contents of the container when full of the blood product(s), sufficient to substantially inactivate viruses contained in the blood product introduced into said container is disclosed. One or more additional products are added to the glycyrrhizic triterpenoid compounds to produce a synergistic affect.

REFERENCES:
Shah et al-Chem. Abst. vol. 100 (1984) p. 56697h.
Yonezawa et al.-Chem. Abst. vol. 103 (1985) p. 76065r.
Yonezawa et al.-Chem. Abst. vol. 98 (1983) p. 185483z.
Shiseido-Chem. Abst. vol. 100 (1984) p. 161681w.

Affiliated with

Also associated with

Rating

Enhanced blood product antiviral process and product produced does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhanced blood product antiviral process and product produced, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced blood product antiviral process and product produced will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1828468